Cyclooxygenase-2: A target for the prevention and treatment of breast cancer

Endocrine-Related Cancer

Volumn 8, Issue 2, 2001, Pages 97-114

  Howe, L R ^a   Subbaramaiah, K ^a   Brown, A M C ^a   Dannenberg, A J ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; PROSTAGLANDIN SYNTHASE;

ADENOMA; BREAST CANCER; CARCINOGENESIS; COLORECTAL CARCINOMA; CONFERENCE PAPER; ENZYME INHIBITION; HUMAN; MAMMARY GLAND; PROTEIN EXPRESSION; RECEPTOR UPREGULATION;

ANIMALS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONAMIDES; UP-REGULATION;

EID: 0034947506     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0080097     Document Type: Conference Paper

References (176)

1. Effects of D,L-2-difluoromethylornithine and indomethacin on mammary tumor promotion in rats fed high n-3 and/or n-6 fat diets
2. Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model
3. Effect of hormonal status on the expression of the cyclooxygenase 1 and 2 genes and prostaglandin synthesis in rat mammary glands
4. The effect of dietary n-3 and n-6 polyunsaturated fatty acids on the expression of cyclooxygenase 1 and 2 and levels of p21ras in rat mammary glands
5. Modulation of the expression of the cyclooxygenase 1 and 2 genes in rat mammary glands: Role of hormonal status and dietary fat
6. Interaction of cyclooxygenases with an apoptosis- and autoimmunity-associated protein
7. Linoleate metabolites enhance the in vitro proliferative response of mouse mammary epithelial cells to epidermal growth factor
8. Prostaglandins and breast cancer
9. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis
10. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens
11. COX-2 expression is induced by UVB exposure in human skin: Implications for the development of skin cancer
12. Intracellular unesterified arachidonic acid signals apoptosis
13. Effect of the prostaglandin synthetase inhibitor indomethacin on 7,12-dimethylbenz(a)anthracene-induced mammary tumorigenesis in rats fed different levels of fat
14. A comparison of the effects of the prostaglandin synthesis inhibitors indomethacin and carprofen on 7,12-dimethylbenz[a]anthracene-induced mammary tumorigenesis in rats fed different amounts of essential fatty acid
15. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck
16. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis
17. Antioxidants reduce cyclooxygenase-2 expression, prostaglandin production, and proliferation in colorectal cancer cells
18. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice
19. The PEA3 subfamily of Ets transcription factors synergizes with β-catenin/LEF-1 to activate matrilysin transcription in intestinal tumors
20. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis
21. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II
22. Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells
23. Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3′-untranslated region
24. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors
25. 1 delay in cells overexpressing prostaglandin endoperoxide synthase-2
26. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
27. Prospective study of regular aspirin use and the risk of breast cancer
28. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: Independence from COX-2 protein expression
29. A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors
30. Initial screening for carcinogenicity of commonly used drugs
31. Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice
32. In vivo effects of indomethacin on the growth of murine mammary tumors
33. The contributions of cyclooxygenase-2 to tumor angiogenesis
34. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
35. The association between a mutated ras gene and cyclooxygenase-2 expression in human breast cancer cell lines
36. Early cell cycle diacylglycerol (DAG) content and protein kinase C (PKC) activity enhancement potentiates prostaglandin F2 alpha (PGF2 alpha) induced mitogenesis in Swiss 3T3 cells
37. Meloxicam inhibits the growth of colorectal cancer cells
38. Reduced risk of large-bowel adenomas among aspirin users
39. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation
40. Strong association between c-myb and oestrogen-receptor expression in human breast cancer
41. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma
42. Regulation of cyclooxygenase-2 and periostin by Wnt-3 in mouse mammary epithelial cells
43. Inhibition by dietary menhaden oil of cyclooxygenase-1 and -2 in N-nitrosomethylurea-induced rat mammary tumors
44. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway
45. Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines
46. Nonsteroidal antiinflammatory drugs and breast cancer
47. Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): An extension of the dietary fat hypothesis of breast cancer
48. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor
49. Prostaglandin synthase 2
50. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas
51. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines
52. Transcriptional activation of cyclooxygenase-2 in Wnt-1-transformed mouse mammary epithelial cells
53. PEA3 is upregulated in response to Wnt1 and activates the expression of cyclooxygenase-2
54. Introduction of full-length APC modulates cyclooxygenase-2 expression in HT-29 human colorectal carcinoma cells at the translational level
55. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2
56. Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production
57. Expression of mitogen-inducible cyclooxygenase induced by lipopolysaccharide: Mediation through both mitogen-activated protein kinase and NF-kappaB signaling pathways in macrophages
58. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer
59. Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element
60. Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam
61. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos
62. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis
63. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing
64. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer
65. Antitumor activity in a rat mammary adenocarcinoma: The effect of cyclooxygenase inhibitors and immunization against prostaglandin E2
66. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
67. Transcriptional regulation of cyclooxygenase-2 in mouse skin carcinoma cells. Regulatory role of CCAAT/enhancer-binding proteins in the differential expression of cyclooxygenase-2 in normal and neoplastic tissues
68. Comparative effects of piroxicam and esculetin on incidence, proliferation, and cell kinetics of mammary carcinomas induced by 7,12-dimethylbenz[a]anthracene in rats on high- and low-fat diets
69. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: Relevance to tumor dedifferentiation
70. Inhibition of NF-kappa B by sodium salicylate and aspirin
71. Cyclooxygenase-2 is overexpressed in human cervical cancer
72. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: Evidence for a transcriptional effect
73. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
74. Aspirin induction of apoptosis in esophageal cancer: A potential for chemoprevention
75. Multiple female reproductive failures in cyclooxygenase 2-deficient mice
76. Cyclooxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARδ
77. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines
78. Overexpression of cyclooxygenase (Cox)-2 is sufficient to induce tumorigenesis in transgenic mice
79. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines
80. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: Case-control study of subjects participating in the Nottingham faecal occult blood screening programme
81. Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts
82. Inhibition of mammary carcinogenesis by flurbiprofen, a non-steroidal antiinflammatory agent
83. Modulation of rat mammary carcinogenesis by indomethacin
84. Significant roles of inducible cyclooxygenase (COX)-2 in angiogenesis in rat sponge implants
85. Aspirin and the potential role of prostaglandins in colon cancer
86. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors
87. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells
88. Retinoids suppress phorbol ester-mediated induction of cyclooxygenase-2
89. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder
90. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs
91. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse
92. Chemoprevention of 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine-induced mammary carcinogenesis in rats
93. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse
94. Suppression of cyclooxygenase-2 promoter-dependent transcriptional activity in colon cancer cells by chemopreventive agents with a resorcin-type structure
95. Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor, in Min mice
96. Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats
97. Effects of the prostaglandin synthetase inhibitor indomethacin on tumorigenesis, tumor proliferation, cell kinetics, and receptor contents of 7,12-dimethylbenz(a)-anthracene-induced mammary carcinoma in Sprague-Dawley rats fed a high- or low-fat diet
98. Role of arachidonic acid metabolism in the mitogenic response of BALB/c 3T3 fibroblasts to epidermal growth factor
99. Cyclooxygenase-2 (COX-2) mRNA expression levels in normal lung tissues and non-small cell lung cancers
100. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas
101. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene
102. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
103. Aspirin use and chronic diseases: A cohort study of the elderly
104. Cyclooxygenase-2 expression in human breast cancer
105. Effects of prostaglandin synthesis inhibitors on tumor growth and vascularization. Experimental studies in the rat
106. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction
107. Inhibition of tumor necrosis factor α-stimulated aromatase activity by microtubule-stabilizing agents, paclitaxel and 2-methoxyestradiol
108. Prostaglandin F2 alpha-induced mitogenesis in MC3T3-E1 osteoblasts: Role of protein kinase-C-mediated tyrosine phosphorylation
109. Myb expression is higher in malignant human colonic carcinoma and premalignant adenomatous polyps than in normal mucosa
110. Cyclooxygenase-2, a colorectal cancer nonsteroidal anti-inflammatory drug target, is regulated by c-MYB
111. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent
112. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats
113. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis
114. Transcriptional regulation of the cyclooxygenase-2 gene in activated mast cells
115. Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women
116. Is inhibition of cyclooxygenase required for the chemopreventive effect of NSAIDs in colon cancer? A model reconciling the current contradiction
117. Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation
118. Expression of cyclooxygenase-2 in human gastric carcinoma
119. Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinomas
120. Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells
121. Omega-3 fatty acids as cancer chemopreventive agents
122. Expression of cyclooxygenase-1 and -2 in human colorectal cancer
123. Δ474 by a novel COX-2 inhibitor, JTE-522
124. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo
125. Aspirin use and lung, colon, and breast cancer incidence in a prospective study
126. 2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators
127. Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells
128. Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage
129. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2
130. 2 in human colon cancer cells
131. Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway
132. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
133. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy
134. Dietary fat and colon cancer: Modulation of cyclooxygenase-2 by types and amount of dietary fat during the postinitiation stage of colon carcinogenesis
135. COX-2 is expressed in human pulmonary, colonic, and mammary tumors
136. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
137. Lung cancer cyclooxygenase-2 dependent inhibition of dendritic cells maturation and function
138. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells
139. Ceramide regulates the transcription of cyclooxygenase-2. Evidence for involvement of extracellular signal-regulated kinase/c-Jun N-terminal kinase and p38 mitogen-activated protein kinase pathways
140. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells
141. Inhibition of cyclooxygenase-2 gene expression by p53
142. Increased expression of cyclooxygenase-2 in HER-2-over expressing human breast cancer cells
143. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 and p38 mitogen-activated protein kinase pathways
144. Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages
145. Aspirin use, cancer, and polyps of the large bowel
146. Inhibitory effects of diallyl disulfide or aspirin on 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced mammary carcinogenesis in rats
147. Activation of matrix metalloproteinase-2 in human breast cancer cells overexpressing cyclooxygenase-1 or -2
148. Studies of prostaglandins in rat mammary tumors induced by 7,12-dimethylbenz(a)anthracene
149. The COX-2 inhibitor nimesulide suppresses superoxide and 8-hydroxy-deoxyguanosine formation, and stimulates apoptosis in mucosa during early colonic inflammation in rats
150. Aspirin use and reduced risk of fatal colon cancer
151. Effects of cyclooxygenase deficiency on inflammation and papilloma development in mouse skin
152. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
153. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
154. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
155. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer
156. Regulation of cyclooxygenase-2 pathway by HER2 receptor
157. Transcriptional activation of the cyclooxygenase-2 gene in endotoxin-treated RAW 264.7 macrophages
158. Carcinogen substrate specificity of human COX-1 and COX-2
159. Elevated cyclooxygenase-2 levels in Min mouse adenomas
160. Host cyclooxygenase-2 modulates carcinoma growth
161. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: Lack of correlation between in vitro and in vivo models
162. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas
163. Expression of cyclooxygenase-2 in human lung carcinoma
164. v-src induces prostaglandin synthase 2 gene expression by activation of the c-Jun N-terminal kinase and the c-Jun transcription factor
165. Transcriptional regulation of prostaglandin synthase 2 gene expression by platelet-derived growth factor and serum
166. The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat
167. Transcriptional roles of nuclear factor κB and nuclear factor-interleukin-6 in the tumor necrosis factor α-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells
168. Sulindac inhibits activation of the NF-κB pathway
169. Benzo[a]pyrene induces the transcription of cyclooxygenase-2 in vascular smooth muscle cells. Evidence for the involvement of extracellular signal-regulated kinase and NF-kappaB
170. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta
171. Expression of cyclooxygenase-2 in prostate carcinoma
172. Dihydroxy bile acids activate the transcription of cyclooxygenase-2
173. Malignant transformation and antineoplastic actions of non-steroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts
174. Lack of cyclooxygenase-2 inhibits growth of teratocarcinomas in mice
175. Posttranscriptional regulation of cyclooxygenase-2 in rat intestinal epithelial cells
176. 2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene